Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17898803 | 0.94 | HPGDS (0.33) | RIPK1PTK2PTK2BGRM5MEN1 | |
| SCHEMBL19091125 | 0.93 | GRM4 (0.34) | RIPK1GRM4PTK2PTK2BGRM5 | |
| SCHEMBL19066904 | 0.93 | GRM4 (0.34) | RIPK1GRM4PTK2PTK2BGRM5 | |
| SCHEMBL17898773 | 0.92 | HPGDS (0.33) | RIPK1PTK2PTK2BGRM5IGF1R | |
| SCHEMBL17899026 | 0.90 | HPGDS (0.31) | RIPK1MEN1CYP1A2KMT2A | |
| SCHEMBL19628479 | 0.90 | RIPK1 (0.34) | RIPK1 | |
| SCHEMBL19099727 | 0.89 | TAS1R3 (0.36) | MEN1KMT2APDE4DTAS1R3TAS1R1 | |
| SCHEMBL17898891 | 0.89 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL17898780 | 0.88 | HPGDS (0.30) | — | |
| SCHEMBL17899024 | 0.88 | HPGDS (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334934-A1 | Macrocyclic picolinamides as fungicides | DOW AGROSCIENCES LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334934-A1 | Macrocyclic picolinamides as fungicides | DOW AGROSCIENCES LLC (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334934-A1 | Macrocyclic picolinamides as fungicides | CYP4F12, CYP1A2, FKBP2 | RIPK1 4127/4885GRM4 1756/4885PTK2 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.